glp·helper
glphelper.com/tirzepatide/florida/hollywood
Dual GIP / GLP-1 receptor agonistFDA-approved May 2022 (Mounjaro) · November 2023 (Zepbound)Rx · Subcutaneous injection · Once weekly

Tirzepatide® providers &
prescriptions in Hollywood, FL

Verified Tirzepatide providers in Hollywood, FL. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

city providers
39
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: Florida
40 of 40 shown

Find a Tirzepatide provider in Florida.

Every entry is checked against the NPI registry and the Florida medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by Florida city · /tirzepatide/florida/{city}
§ 03Getting Tirzepatide in Hollywood
40 providers · Hollywood, FL

How to get Tirzepatide in Hollywood.

40 GLP-1 prescribers and 7 local resource types are on record for Hollywood, plus 3 nearby towns in the directory.

Prescribers in Hollywood
40 prescribers
40 GLP-1 prescribers in Hollywood, most listed as Internal Medicine, Endocrinology, Diabetes & Metabolism (15), Family Medicine (13) and Internal Medicine (9). Any Florida-licensed physician, nurse practitioner, or PA can prescribe Tirzepatide, over video or in person. The nearest towns on record are North Miami Beach (24 providers), Fort Lauderdale (41 providers) and Davie (35 providers).
Around the prescription in Hollywood
7 listed nearby
46 dietitians, 6 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 6 places to move are on record near Hollywood.
Medicaid (weight loss)
Diabetes only
As of April 2026, Florida Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Florida’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

The molecule in Mounjaro and Zepbound. It acts on two gut-hormone pathways, GIP and GLP-1.

Tirzepatide is a once-weekly injection sold by Eli Lilly as Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management). It is the first approved dual GIP/GLP-1 receptor agonist. It activates two gut-hormone pathways rather than one, which is associated with greater average weight loss than single GLP-1 agonists.[2][3]

In SURMOUNT-1, adults with obesity (without diabetes) lost a mean of 20.9% of body weight on the 15 mg dose at 72 weeks, versus 3.1% on placebo. In the SURPASS-2 head-to-head diabetes trial, tirzepatide produced larger HbA1c and weight reductions than semaglutide 1 mg.[1]

At a glanceMultiple (brand-specific)
Generic name
tirzepatide
Drug class
Dual GIP / GLP-1 receptor agonist
Manufacturer
Eli Lilly
FDA approved
May 2022 (Mounjaro) · November 2023 (Zepbound)
Approved use
Type 2 diabetes (Mounjaro) · chronic weight management (Zepbound)
Off-label use
Use outside the approved brand/indication is off-label
Administration
Subcutaneous injection · Once weekly
Available doses
2.5 mg · 5 mg · 7.5 mg · 10 mg · 12.5 mg · 15 mg
Half-life
≈ 5 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy; may reduce oral contraceptive efficacy

Community health · CDC

Weight & metabolic health in Hollywood

Hollywood, Florida has a population of 153,067 people. The adult obesity rate in Hollywood is an age-adjusted estimate of 30.3%, 0.7 percentage points above the Florida state rate of 29.6%. Diagnosed diabetes reaches 11.4% of adults in Hollywood. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 26.1% of adults in Hollywood.

of Hollywood adults have obesity
30.3%
diagnosed diabetes
11.4%
no regular physical activity
26.1%

Age-adjusted estimates for Hollywood, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight lossthe tirzepatide dosing schedule
§ 05Support around Tirzepatide in Hollywood
6 dietitians

The prescription is one part. Here is the rest, in Hollywood.

Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near Hollywood, FL, ordered as the registry lists them, never by who pays us.

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Elvira Alvarez Stehle
RD
Registered dietitian
929 Harbor Vw N
Call 305-332-3939NPI 1255211827
Leah Amar, R.D
RD
Registered dietitian
4721 Sarazen Dr
Call 954-966-7439NPI 1407031842
Jenna Appel, RD
RD
Registered dietitian
1295 Nw 40Th Ave Ste 200
Call 954-583-4710NPI 1467954446
Frances Asencio, MS, RD, LDN, CNSC
RD
Registered dietitian
1919 Van Buren St Apt 121A
Call 973-474-0665NPI 1831732122
Gitit Bachiry, RDN
RD
Registered dietitian
3800 N Hills Dr Apt 408
Call 347-259-7331NPI 1053272799
Jannell Baez, RD, LD/N
RD
Registered dietitian
1930 Harrison St Ste 404
Call 786-780-1188NPI 1710865043

Nutritionists

A nutritionist helps you get enough protein and fiber while the medication cuts your appetite. Call to ask what they cover.

Tessa Florio, M.S. Nutrition
NUTRITIONIST
Nutritionist
1040 Eucalyptus Dr Unit 6
Call 618-709-2239NPI 1023838489
Ana Grimsley, RDN, LD/N
NUTRITIONIST
Nutritionist
6478 Moseley St
Call 305-498-0995NPI 1588117667
Arlene Kasner, NC
NUTRITIONIST
Nutritionist
3475 Sheridan St
Call 954-986-6400NPI 1881948347
Michelle Stewart, MPH, RD, LD, N, CDE
NUTRITIONIST
Nutritionist
1050 Satinleaf St
Call 954-927-9062NPI 1861769531
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the SURMOUNT weight-management program and the SURPASS diabetes program, including the SURPASS-2 head-to-head against semaglutide. Figures are means at each trial's primary endpoint.

SURMOUNT-1 randomized 2,539 adults with obesity (without diabetes) across 72 weeks. Mean weight change was −15.0% (5 mg), −19.5% (10 mg), and −20.9% (15 mg) versus −3.1% with placebo. A majority of patients on the higher doses lost ≥20% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (15 mg)
−20.9%
SURMOUNT-1, 72 wk vs −3.1% placebo[2]
Mean weight change (5 mg)
−15.0%
SURMOUNT-1, 72 wk[2]
HbA1c reduction (T2D)
−1.8 to −2.6%
SURPASS program[4]
vs. semaglutide 1 mg
Superior
SURPASS-2, HbA1c + weight[3]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average tirzepatide weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
12 to 24%
mild
Dose-dependent; usually eases after titration
Diarrhea
12 to 19%
mild
More frequent during dose escalation
Vomiting
5 to 13%
mild
Reduced by slower titration
Constipation
6 to 17%
mild
Decreased appetite
5 to 11%
mild
Expected pharmacologic effect
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
~1 to 2%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash, Zepbound (no insurance)
$1,000 to $1,300
per month
Brand-name retail; Lilly self-pay vials lower for some doses[6]
Cash, Mounjaro (no insurance)
$1,000 to $1,200
per month
Brand-name retail average[6]
Commercial insurance (T2D)
$25 to $250
per month copay
Usually covered for diabetes with prior authorization
Commercial insurance (weight)
Often denied
Zepbound is on-label but frequently requires PA
Medicare Part D
$0 to $100
per month
T2D covered; weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $25
per month
Commercial insurance only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Tirzepatide providers in Florida

NPI-verified Tirzepatide (tirzepatide) prescribers and clinics, ordered by availability, never by who pays us.

Tirzepatide in other states

Find NPI-verified Tirzepatide (tirzepatide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Related GLP-1 research
§ 09Frequently asked: Tirzepatide in Florida

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Tirzepatide is the active molecule in both Eli Lilly products. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. They are the same drug with different approved indications, and insurers treat them as separate products.[1]